Medical News Today -
4 Mar 2014 12:00
Boehringer Ingelheim has announced new data from large scale, Phase III studies showing that once-daily tiotropium delivered via the Respimat® Soft Mist™ Inhaler improved lung function and was well tolerated in patients with varying degrees of asthma severity.1 These data were presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2014 annual meeting in San Diego. The first results from the Phase III GraziaTinA-asthma® study demonstrated that tiotropium Respimat® 5 mcg an...
Share this Article